Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, United States.
Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, United States.
Genomics. 2020 Jul;112(4):2703-2712. doi: 10.1016/j.ygeno.2020.03.004. Epub 2020 Mar 5.
Arthrofibrosis is an abnormal histopathologic response, is debilitating for patients, and poses a substantial unsolved clinical challenge. This study characterizes molecular biomarkers and regulatory pathways associated with arthrofibrosis by comparing fibrotic and non-fibrotic human knee tissue. The fibrotic group encompasses 4 patients undergoing a revision total knee arthroplasty (TKA) for arthrofibrosis (RTKA-A) while the non-fibrotic group includes 4 patients undergoing primary TKA for osteoarthritis (PTKA) and 4 patients undergoing revision TKA for non-arthrofibrotic and non-infectious etiologies (RTKA-NA). RNA-sequencing of posterior capsule specimens revealed differences in gene expression between each patient group by hierarchical clustering, principal component analysis, and correlation analyses. Multiple differentially expressed genes (DEGs) were defined in RTKA-A versus PTKA patients (i.e., 2059 up-regulated and 1795 down-regulated genes) and RTKA-A versus RTKA-NA patients (i.e., 3255 up-regulated and 3683 down-regulated genes). Our findings define molecular and pathological markers of arthrofibrosis, as well as novel potential targets for risk profiling, early diagnosis and pharmacological treatment of patients.
关节纤维组织增生是一种异常的组织病理学反应,使患者身体虚弱,并带来了巨大的未解决的临床挑战。本研究通过比较纤维性和非纤维性人类膝关节组织,来确定与关节纤维组织增生相关的分子生物标志物和调节途径。纤维性组包括 4 名因关节纤维组织增生而行翻修全膝关节置换术(RTKA-A)的患者,而非纤维性组包括 4 名因骨关节炎而行初次全膝关节置换术(PTKA)的患者和 4 名因非关节纤维组织增生性和非传染性病因而行翻修全膝关节置换术(RTKA-NA)的患者。对后囊标本进行 RNA 测序,通过层次聚类、主成分分析和相关分析,揭示了每组患者之间基因表达的差异。在 RTKA-A 与 PTKA 患者之间(即 2059 个上调和 1795 个下调基因)和 RTKA-A 与 RTKA-NA 患者之间(即 3255 个上调和 3683 个下调基因)定义了多个差异表达基因(DEGs)。我们的研究结果定义了关节纤维组织增生的分子和病理学标志物,以及用于风险分析、早期诊断和药物治疗患者的新的潜在靶点。